BUY WINSTROL OIL BASE (STANOZOLOL) (100 MG/ML – 10 ML)
MAIN PRODUCT DESCRIPTION
Product Overview & Pharmaceutical Specifications
Winstrol Oil Base 100 (Stanozolol) 100 mg/ml – 10 ml is described in the supplied information as an anabolic-androgenic steroid preparation containing stanozolol. The product is presented in a 10 ml vial with a stated concentration of 100 mg/ml.
Stanozolol is a synthetic anabolic-androgenic steroid structurally related to dihydrotestosterone (DHT). It has been used historically in pharmaceutical contexts, while also becoming widely associated with athletic and bodybuilding communities.
The supplied source contains several promotional claims concerning fat reduction, muscle definition, strength and endurance. These claims are not presented here as guaranteed clinical outcomes. The product’s appropriate medical status and indications should be established from current official regulatory and prescribing documentation.
Product Specifications
Product: Winstrol Oil Base 100
Active Ingredient: Stanozolol
Strength: 100 mg/ml
Pack Size: 10 ml
Dosage Form: Injectable preparation
Route: Injection
Drug Class: Anabolic-androgenic steroid
Manufacturer stated: Geber Pharmaceuticals
Market Status: Not supplied
Molecular Formula: Not supplied
Molecular Weight: Not supplied
Storage: Below 30°C; protect from sunlight
Pharmacological Classification
Stanozolol is an anabolic-androgenic steroid (AAS). Its biological activity is associated with interaction with androgen receptors, which are intracellular receptors responsible for mediating many effects of androgenic hormones.
Androgen-receptor signalling can influence multiple tissues, including skeletal muscle, bone, reproductive tissues and skin. Consequently, stanozolol should not be considered a substance that acts exclusively on muscle.
The supplied source describes stanozolol as having anabolic and androgenic activity. These terms refer to two related categories of androgen action: effects associated with tissue-building processes and effects associated with male sexual characteristics.
Relationship to Dihydrotestosterone
The supplied material describes stanozolol as a derivative of dihydrotestosterone. This provides relevant context for understanding its pharmacological classification.
The source also makes claims concerning anti-oestrogenic and progesterone-related activity. These descriptions have not been expanded into therapeutic claims because the supplied information does not provide sufficient evidence to establish a specific clinical use for these effects.
Pharmaceutical and Historical Context
The source states that stanozolol became known in injectable form during the 1960s and describes historical use in pharmaceutical settings.
Historically, stanozolol has been investigated and used for specific medical purposes, but regulatory status and authorised indications differ by jurisdiction and product. No current European marketing authorisation documentation was supplied for this specific Winstrol Oil Base presentation.
Accordingly, the historical information should not be interpreted as evidence that this particular product is currently authorised in the European Union.
Body Composition and Athletic Claims
The supplied source associates Winstrol Oil Base 100 with:
Muscle definition
Reduced body fat
Strength
Endurance
Changes in body composition
Reduced apparent water retention
These statements reflect the product’s bodybuilding-oriented marketing context. They are not presented here as guaranteed medical benefits.
In particular, the source’s claim that stanozolol reliably produces fat loss or creates a specific “dry” or defined appearance should not be treated as an established clinical outcome.
Androgenic Activity
As an androgenic steroid, stanozolol can influence androgen-sensitive tissues. The supplied source lists possible effects involving sexual function, hair growth, skin, voice and reproductive physiology.
These effects are relevant to understanding why androgenic steroids require careful medical assessment. The statement in the source that the product does not cause adverse reactions when used correctly has not been retained as a safety guarantee.
Potential Adverse Effects
The supplied material identifies several possible adverse effects associated with stanozolol, including:
Hypersensitivity reactions
Swelling of the hands, feet or ankles
Prolonged or excessive erections
Breast tenderness or enlargement
Voice changes
Hair loss
Increased facial hair
Clitoral enlargement
Menstrual irregularities
Acne
Sleep disturbances
Headache
Changes in sexual desire
Some of these effects can be particularly relevant to androgen-sensitive individuals and may require medical assessment.
The supplied source does not provide a complete modern safety profile for the specific formulation, so no claim is made that the product is safe or free from serious adverse effects.
Hepatic and Metabolic Considerations
The supplied material makes several statements about stanozolol and liver metabolism, including comparisons between oral and injectable forms.
These claims should be treated cautiously. A particular route of administration does not automatically eliminate the potential for systemic adverse effects. Stanozolol can influence metabolic and endocrine systems, and appropriate clinical monitoring should depend on the patient’s circumstances.
No claim has been made that the injectable presentation is free from hepatic, cardiovascular or endocrine risk.
Female Use
The source contains statements about use by women but also lists possible androgen-related effects such as voice changes, increased facial hair, clitoral enlargement and menstrual irregularities.
These effects illustrate the potential for virilising effects in women. The product should therefore not be promoted for routine female use without a specific medical indication and professional supervision.
Endocrine Effects
Anabolic-androgenic steroids can influence endogenous hormonal signalling. Stanozolol’s interaction with androgen receptors can affect the body’s normal endocrine feedback mechanisms.
The supplied source does not provide a complete assessment of endocrine suppression, reproductive effects or long-term hormonal outcomes for this specific presentation.
For this reason, the product should not be described as hormonally neutral or as free from endocrine consequences.
Administration Information
The supplied source includes specific athletic dosing schedules and cycle durations. Those instructions have not been reproduced because they would constitute practical guidance for non-prescribed use of an anabolic steroid.
The stated 100 mg/ml refers to product concentration and should not be interpreted as an individual patient dose.
Any medicinal use should follow the official prescribing information applicable to the specific authorised product and the direction of a qualified healthcare professional.
Combination and Stacking Claims
The source discusses combining stanozolol with other anabolic steroids. These combinations have not been presented as recommendations.
Combining multiple anabolic-androgenic steroids can increase total pharmacological exposure and may complicate assessment of adverse reactions and drug interactions. No evidence supplied with this product establishes such combinations as safe or appropriate.
Product Authentication
The supplied material states that each vial contains 10 ml at 100 mg/ml and that the packaging carries a hologram and a unique erasable code intended for product verification.
These authentication features have not been independently verified. Customers should rely on current manufacturer documentation and appropriate regulatory or pharmaceutical verification rather than treating packaging claims alone as proof of authenticity.
Manufacturer Information
The supplied source identifies Geber Pharmaceuticals as the manufacturer.
No additional information regarding manufacturing standards, GMP certification, batch-release testing or certificate of analysis was supplied.
Formulation Consistency
There is an important inconsistency in the source material. The product title identifies the preparation as “Oil Base”, while another section describes it as an aqueous form of injection.
This discrepancy should be resolved using the current product label, technical documentation and certificate of analysis before the listing makes a definitive claim about the vehicle or formulation.
Regulatory Considerations
No EU marketing authorisation, national European authorisation number or verified regulatory classification was supplied for Winstrol Oil Base 100.
Therefore, the product should not be described as EU-approved, prescription-free or legally saleable throughout Europe without verification from the relevant national medicines authority.
Storage
The supplied source recommends:
Store at room temperature below 30°C and protect from sunlight.
The product should be kept according to the current manufacturer’s official storage instructions.
Important Pharmaceutical Disclaimer
Winstrol Oil Base 100 contains a pharmacologically active anabolic-androgenic steroid. The original source includes bodybuilding and performance-related claims, but those claims have not been presented as established therapeutic benefits.
This description is based on the information supplied and does not replace official prescribing information or qualified medical advice. Before publication, the formulation, manufacturer details, regulatory status and packaging specifications should be verified against current official documentation.
